Filing Details

Accession Number:
0001209191-22-006385
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-02 16:34:38
Reporting Period:
2022-01-31
Accepted Time:
2022-02-02 16:34:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1668243 Urogen Pharma Ltd. URGN () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1363812 Molly Henderson 400 Alexander Park Drive
Princeton NJ 08540
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2022-01-31 666 $0.00 5,579 No 4 M Direct
Ordinary Shares Disposition 2022-01-31 331 $7.58 5,248 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Stock Units Disposition 2022-01-31 666 $0.00 1,334 $0.00
Ordinary Shares Restricted Stock Units Acquisiton 2022-01-31 7,500 $0.00 7,500 $0.00
Ordinary Shares Stock Option (right to buy) Acquisiton 2022-01-31 30,000 $0.00 30,000 $7.72
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,334 No 4 M Direct
7,500 No 4 A Direct
30,000 2032-01-31 No 4 A Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
  2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
  3. The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022.
  4. 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.
  5. 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025.